Physician profile
Carnai Simpson
NPI 1437531118
$4,083.64
in general payments reported to CMS, 2019-2025
28 companies · $613 in 2025
The $613 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $955 · 2020: $871 · 2021: $558 · 2022: $389 · 2023: $183 · 2024: $515 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,310.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,540.07 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $742.95 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $352.05 | 2019-2024 | Mounjaro |
| Merck Sharp & Dohme LLC | $300.94 | 2019-2025 | Verquvo |
| Abbvie INC. | $156.00 | 2021-2024 | Ubrelvy |
| Abbott Laboratories | $133.36 | 2021-2024 | Freestyle Libre 3 |
| Amgen INC. | $112.31 | 2021-2025 | Repatha, Otezla, Repatha |
| Intersect Ent, INC. | $104.00 | 2019 | |
| Alnylam Pharmaceuticals INC. | $73.99 | 2025 | |
| Allergan, INC. | $66.12 | 2020 | |
| Pfizer INC. | $47.24 | 2020-2025 | |
| Glaxosmithkline, LLC. | $46.99 | 2019-2023 | Shingrix |
| Bridgebio Pharma, INC. | $44.93 | 2025 | Attruby |
| Cranial Technologies, INC | $43.42 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $39.74 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $37.83 | 2023 | Krystexxa |
| Phadia US INC. | $36.38 | 2019 | |
| Sanofi-Aventis U.S. LLC | $26.15 | 2020-2021 | |
| Sanofi Pasteur INC. | $25.70 | 2019 | |
| Edwards Lifesciences Corporation | $24.30 | 2025 | Sapien 3 Ultra Resilia |
| Gilead Sciences, INC. | $24.03 | 2019-2020 | |
| Neos Therapeutics, LP | $21.24 | 2019 | |
| Exact Sciences Corporation | $19.95 | 2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $15.33 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.06 | 2021 | |
| Mylan Specialty L.P. | $12.18 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.95 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carnai Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.